^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS
Published date:
11/09/2020
Excerpt:
We identified a cohort of metastatic EGFR/ALK wild type NSCLC patients...Among patients who received pembrolizumab monotherapy, there was a trend toward increased risk of death in those with STK11 mutations [HR=17.54; CI=0.35–1,000; p=0.15].
Source:
Title:
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
Excerpt:
66 patients with non-squamous NSCLC treated with PD-1/PD-L1 inhibitors at MDACC (61% pembrolizumab, 24% nivolumab, 8% atezolizumab, 5% durvalumab/tremelimumab) with available STK11/LKB1 NGS-based genomic profiling and positive tumor cell PD-L1 expression...STK11/LKB1 genomic alterations are associated with de novo resistance to PD-1/PD-L1 inhibitors even among PD-L1-positive non-squamous NSCLC patients, suggesting that their effect is at least partially independent of PD-L1 expression.
DOI:
10.1200/JCO.2018.36.15_suppl.9028
Source:
Title:
Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
Published date:
02/23/2022
Excerpt:
CONTRADICTORY EVIDENCE: We studied the impact of metformin on ICI efficacy in STK11 mutant NSCLC in vitro and in vivo using colony formation assay....In NOD-SCID xenografts, metformin in combination with PD-1 inhibitor pembrolizumab effectively decreased tumor growth and increased infiltration of CD8+ T cells.
Secondary therapy:
metformin
DOI:
https://doi.org/10.3389/fmolb.2022.780200
